Litigation

Recent Posts

AstraZeneca Paying $68.5 Million In Seroquel Settlement
Posted on 12 Mar 2011 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. - (AP) AstraZeneca will pay $68.5 million as part of a multistate settlement over allegations that the drug developer promoted its blockbuster psychiatric drug Seroquel for insomnia, Alzheimer's and other unapproved uses. The New... Read More

Tags: off-label use , AstraZeneca , New Jersey , New Jersey Attorney General , Litigation , lawsuit , blockbuster drug , Seroquel , antipsychotic drug

AstraZeneca Pays States $68.5M For Off-Label Marketing Of Seroquel Antipsychotic
Posted on 11 Mar 2011 by Tom Moylan

TRENTON, N.J. - (Mealey's) AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. on March 10 agreed to pay $68.5 million to 37 states and the District of Columbia to resolve allegations in a New Jersey state court lawsuit that it marketed its atypical... Read More

Tags: off-label use , Dow v. AstraZeneca , Risperdal , AstraZeneca , New Jersey Attorney General , Litigation , Zyprexa , Seroquel , antipsychotic drug

Novo Nordisk Pays $26.7 Million To Settle Off-Label, Improper Payment Lawsuits
Posted on 13 Jun 2011 by Tom Moylan

(Mealey's) Danish drug and biologics maker Novo Nordisk will pay a total of $26.7 million to settle separate False Claims Act lawsuits that include allegations that it paid military doctors to use a hemophilia drug off-label on wounded soldiers and... Read More

Tags: False Claims Act , hemophilia drug , off-label use , Ian Black , Novo Nordisk , Oscar Montier , United States of America v. Novo Nordisk , Litigation , lawsuit , NovoSeven

Medtronic Escapes Fraud Claims In Off-Label Stent Litigation
Posted on 28 Jul 2011 by Tom Moylan

BOSTON - (Mealey's) Finding that two whistle-blowers' False Claims Act (FCA) allegations failed to meet federal pleading requirements for fraud, a Massachusetts federal judge on July 27 dismissed claims that Medtronic Inc. promoted biliary stents... Read More

Tags: False Claims Act , off-label use , FCA , United States ex rel. Wall v. Vista Hospice Care , Fraud , Medtronic , United States of America v. Medtronic , Enda Dodd , Litigation , whistle-blower , Federal Rule of Civil Procedure 9(b)